NADAC acquisition cost data for DIFICID 200 MG TABLET. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 52015008001 | $214.53 | 2022-01-06 | Rx |
| 52015008001 | $214.53 | 2022-01-06 | Rx |
| 52015008001 | $214.53 | 2022-01-06 | Rx |
| 52015008001 | $214.53 | 2022-01-06 | Rx |
| 52015008001 | $214.53 | 2022-01-06 | Rx |
| 52015008001 | $214.53 | 2022-01-06 | Rx |
| 52015008001 | $214.53 | 2022-01-06 | Rx |
| 52015008001 | $214.53 | 2022-01-06 | Rx |
| 52015008001 | $214.53 | 2022-01-06 | Rx |
| 52015008001 | $214.53 | 2022-01-06 | Rx |
Generic: Fidaxomicin | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $44.5M | 11,904 | 9,154 | $197.42 |
| 2020 | $47.4M | 11,989 | 8,600 | $207.42 |
| 2021 | $68.0M | 16,400 | 11,968 | $218.49 |
| 2022 | $103.1M | 24,035 | 18,221 | $231.58 |
| 2023 | $127.2M | 28,662 | 21,562 | $244.78 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $11.7M | 2,703 | 2,081 |
| New York | $11.0M | 2,398 | 1,726 |
| Texas | $9.0M | 1,994 | 1,561 |
| Florida | $7.9M | 1,823 | 1,446 |
| Illinois | $5.9M | 1,312 | 968 |
| Pennsylvania | $5.7M | 1,287 | 996 |
| Ohio | $5.6M | 1,306 | 960 |
| North Carolina | $5.0M | 1,137 | 872 |
| Georgia | $4.5M | 993 | 782 |
| New Jersey | $4.2M | 970 | 717 |
| Michigan | $3.7M | 864 | 662 |
| Massachusetts | $3.3M | 760 | 580 |
| Colorado | $2.9M | 690 | 540 |
| Virginia | $2.8M | 658 | 507 |
| Indiana | $2.7M | 599 | 472 |
| Maryland | $2.7M | 563 | 417 |
| Wisconsin | $2.7M | 605 | 457 |
| Tennessee | $2.5M | 551 | 438 |
| Arizona | $2.4M | 547 | 443 |
| Missouri | $2.3M | 521 | 400 |
| Kentucky | $2.2M | 486 | 397 |
| Minnesota | $2.1M | 480 | 364 |
| Washington | $1.9M | 435 | 346 |
| Connecticut | $1.9M | 392 | 303 |
| South Carolina | $1.9M | 442 | 356 |
| Louisiana | $1.7M | 372 | 294 |
| Alabama | $1.6M | 348 | 281 |
| Oklahoma | $1.5M | 336 | 265 |
| West Virginia | $1.1M | 254 | 201 |
| Oregon | $1.1M | 244 | 191 |
| Nevada | $1.0M | 218 | 160 |
| Kansas | $1.0M | 241 | 195 |
| Arkansas | $1.0M | 217 | 178 |
| Iowa | $934.4K | 204 | 173 |
| Maine | $890.7K | 188 | 136 |
| Mississippi | $844.8K | 184 | 151 |
| New Hampshire | $674.2K | 144 | 111 |
| Idaho | $666.2K | 142 | 110 |
| New Mexico | $630.9K | 144 | 120 |
| Utah | $467.4K | 104 | 88 |
| Nebraska | $457.9K | 111 | 95 |
| Rhode Island | $403.7K | 94 | 73 |
| Delaware | $401.5K | 88 | 66 |
| Vermont | $400.3K | 78 | 56 |
| Hawaii | $367.3K | 85 | 60 |
| North Dakota | $302.1K | 69 | 60 |
| South Dakota | $250.2K | 56 | 46 |
| District of Columbia | $234.8K | 51 | 48 |
| Alaska | $207.1K | 46 | 42 |
| Montana | $188.8K | 46 | 38 |
| Wyoming | $167.2K | 36 | 32 |
| Puerto Rico | $81.5K | 18 | 17 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.